Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Spironolactone for the Treatment of Melasma
NCT03953209 · Medical University of South Carolina · PHASE1 · withdrawn · last registry update 2024-09-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Conflict with funding” | – | Registry record, Medical University of South Carolina |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against NR3C2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-08-28Phase 3 first posted: Centre Hospitalier St Anne, Cilostazol (Pletal®) 100 mg Tablets + Placebo (NCT07144956)
- 2025-08-26Results posted on the registry: Bayer, Finerenone (BAY94-8862) (NCT04435626)
- 2025-08-08Results posted on the registry: Vrije Universiteit Brussel, Intravenous acetazolamide 500 mg OD + Intravenous bumetanide TID (NCT05411991)
- 2025-07-09Results posted on the registry: AstraZeneca, Sodium zirconium cyclosilicate + Placebo (NCT04676646)
- 2025-07-02Phase 3 first posted: Sarfez Pharmaceuticals, Inc., Torsemide and Spironolactone tablet + Torsemide Tablets and Spironolactone Tablets (NCT07046975)
- 2025-06-29Phase 3 first posted: Sarfez Pharmaceuticals, Inc., FDC (24 mg ER torsemide and 30 mg Spironolactone) without food + FDC (24 mg ER torsemide and 30 mg Spironolactone) with food (NCT07043634)
- 2025-06-25Phase 3 first posted: Centre Hospitalier Universitaire, Amiens, hydrocortisone plus fludrocortisone + placebo of hydrocortisone plus fludrocortisone (NCT07037043)
- 2025-06-12Results posted on the registry: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Fludrocortisone + Hydrocortisone (NCT00001521)
- 2025-06-11Phase 3 first posted: Sarfez Pharmaceuticals, Inc., 10 mg Torsemide tablet + 25 mg Aldactone (Spironolactone) tablet (NCT07015671)
- 2025-03-28Also stopped (terminated): Charite University, Berlin, Germany, Experimental: Spironolactone + Placebo Comparator (NCT04727073)
- 2025-03-26Results posted on the registry: University of California, San Francisco, Spironolactone 100mg + Placebo oral capsule (NCT03576755)
- 2025-03-26Results posted on the registry: Thomas Jefferson University, Doravirine/Lamivudine/Tenofovir + Spironolactone 100mg (NCT04283656)
- 2025-03-21Results posted on the registry: Pfizer, Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris + Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma. (NCT06205407)
- 2025-03-19Results posted on the registry: Brigham and Women's Hospital, Eplerenone vs Amlodipine (NCT03683069)
- 2025-03-04Results posted on the registry: NHS Greater Glasgow and Clyde, Patiromer (NCT04142788)
- 2025-03-04Also stopped (terminated): NHS Greater Glasgow and Clyde, Patiromer (NCT04142788)
- 2025-02-24Results posted on the registry: Boehringer Ingelheim, Yasmin® + BI 1358894 (NCT05934942)
- 2025-02-24Also stopped (terminated): Boehringer Ingelheim, Yasmin® + BI 1358894 (NCT05934942)
- 2025-02-21Results posted on the registry: James J. Peters Veterans Affairs Medical Center, Midodrine Hydrochloride + Midodrine Hydrochloride (NCT02919917)
- 2024-12-05Phase 3 first posted: Istanbul Medeniyet University, a drug against NR3C2 (NCT06717633)
- 2024-11-26Results posted on the registry: Washington University School of Medicine, Transdermal patch + Daily Sublingual Tablet (NCT05010707)
- 2024-11-21Also stopped (terminated): The George Institute, Low dose combination polydiuretic therapy + Comparator monotherapy empagliflozin (NCT05129722)
- 2024-11-07Phase 3 first posted: Qilu Hospital of Shandong University, .spironolactone (NCT06678685)
- 2024-09-25Also stopped (terminated): Iain Bressendorff, ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib (NCT05897372)
- 2024-09-19Also stopped (withdrawn): Medical University of South Carolina, Spironolactone 50 MG + Spironolactone 100mg (NCT04100083)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision